In endometrial cancer, PD-1 blockade combined with chemotherapy has improved outcomes, and pembrolizumab has demonstrated clinically meaningful activity in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) solid tumors, including gynecological cancers [12,13]. The gene discussed is PDCD1; the disease is endometrial cancer.